RETEVMO (selpercatinib)

**Product type:** Human Prescription Drug

**Active ingredient:** SELPERCATINIB

**Strength:** 160 mg/1

**Dosage form:** Tablet, Coated

**Route:** Oral

**Labeler:** Eli Lilly and Company

**Marketing category:** NDA (NDA218160)

**Pharmacologic class:** Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]